Effectdossier · gearchiveerd kwartaal
ACRS
Aclaris Therapeutics, Inc. · Healthcare · Biotechnology
65Gevolgde houders
-2Δ houders
41.75MGehouden aandelen
$156.42MGerapporteerde waarde
+5Nieuwe posities
−7Uitstappen
Momentum-inputs (vergelijkbare managers):
breedte van houders -3.0% ·
aandelenstroom +6.8% ·
netto nieuwe posities -3.1%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2026
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 154.55K | $812,954 | n/a | n/a |
| Q2 2026 | 60 | -2 | 41.91M | $221.50M | +3 | −6 |
| Q1 2026 | 65 | -2 | 41.75M | $156.42M | +5 | −7 |
| Q4 2025 | 67 | +2 | 40.44M | $121.72M | +2 | n/a |
| Q3 2025 | 17 | +1 | 36.82M | $69.96M | +1 | n/a |
| Q2 2025 | 13 | 0 | 38.17M | $54.21M | n/a | n/a |
| Q1 2025 | 10 | 0 | 23.63M | $36.15M | n/a | n/a |
| Q4 2024 | 10 | +2 | 20.49M | $50.82M | +2 | n/a |
| Q3 2024 | 7 | -1 | 10.01M | $11.51M | n/a | −1 |
| Q2 2024 | 8 | n/a | 10.87M | $11.95M | n/a | n/a |
Wie het bezit · Q1 2026
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 3.87M | +14.8% | $14.52M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 2 | Balyasny Asset Management L.P. | 3.36M | Nieuw | $12.60M | 0.0% | New | 1 | SEC ↗ |
| 3 | Morgan Stanley ✦ | 2.75M | -19.6% | $10.30M | 0.0% | ▼ Trim | 3 | SEC ↗ ×6 |
| 4 | Geode Capital Management ✦ (passief) | 2.42M | +1.3% | $9.09M | 0.0% | ▲ Add | 8 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passief) | 2.01M | +33.4% | $7.53M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | Deutsche Bank Ag\ | 997.85K | +1.1% | $3.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 900.80K | -57.0% | $3.38M | 0.0% | ▼ Trim | 8 | SEC ↗ |
| 8 | Northern Trust Corp | 728.23K | +9.6% | $2.73M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 9 | Goldman Sachs Group ✦ | 588.69K | -6.9% | $2.21M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 10 | Dimensional Fund Advisors Lp | 511.46K | +88.8% | $1.91M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 502.63K | -55.3% | $1.88M | 0.0% | ▼ Trim | 8 | SEC ↗ |
| 12 | JPMorgan Chase ✦ | 486.63K | -22.3% | $1.70M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 13 | Two Sigma Investments ✦ | 395.64K | -31.1% | $1.48M | 0.0% | ▼ Trim | 8 | SEC ↗ |
| 14 | Raymond James Financial Inc | 266.45K | -1.2% | $999,181 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Charles Schwab Investment… | 260.99K | -8.3% | $978,713 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Wellington Management ✦ | 257.16K | -2.7% | $964,335 | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 17 | Sei Investments Co | 217.15K | Nieuw | $814,328 | 0.0% | New | 1 | SEC ↗ |
| 18 | Invesco Ltd. | 214.94K | +2.4% | $806,007 | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 19 | Mackenzie Financial Corp | 213.41K | Nieuw | $800,269 | 0.0% | New | 1 | SEC ↗ |
| 20 | Fidelity (FMR) ✦ | 176.35K | +285.0% | $661,324 | 0.0% | ▲ Add | 4 | SEC ↗ ×3 |
| 21 | T. Rowe Price ✦ | 156.72K | +11.8% | $588,000 | 0.0% | ▲ Add | 8 | SEC ↗ |
| 22 | American Century Companies Inc | 118.70K | +53.0% | $445,133 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | Bank Of America Corp /De/ | 79.54K | +23.3% | $298,271 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | Rhumbline Advisers | 75.40K | +5.0% | $282,749 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 72.41K | -30.2% | $271,530 | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 26 | Wells Fargo & Company/Mn | 36.26K | -65.3% | $135,983 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 27 | New York State Common Retirement… | 27.30K | 0.0% | $102,375 | 0.0% | Held | 2 | SEC ↗ |
| 28 | Manufacturers Life Insurance… | 25.40K | -12.4% | $95,243 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 29 | Barclays Plc | 21.51K | -85.0% | $80,654 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 30 | Bnp Paribas Financial Markets | 21.45K | -0.3% | $80,419 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 31 | CIBC Asset Management Inc | 17.43K | 0.0% | $65,355 | 0.0% | Held | 2 | SEC ↗ |
| 32 | Voya Investment Management Llc | 16.31K | -5.4% | $61,166 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 33 | Prudential Financial Inc | 13.38K | Nieuw | $50,175 | 0.0% | New | 1 | SEC ↗ |
| 34 | Alliancebernstein L.P. | 15.20K | 0.0% | $45,752 | 0.0% | Held | 2 | SEC ↗ |
| 35 | Victory Capital Management Inc | 11.75K | +10.3% | $44,059 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 36 | Mercer Global Advisors Inc /Adv | 10.60K | +4.2% | $39,731 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 37 | Legal & General Group Plc | 8.24K | 0.0% | $30,908 | 0.0% | Held | 2 | SEC ↗ |
| 38 | Citigroup Inc | 7.83K | -81.2% | $29,348 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 39 | California State Teachers… | 4.96K | -12.1% | $18,619 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 40 | Pnc Financial Services Group, Inc. | 2.07K | 0.0% | $7,763 | 0.0% | Held | 2 | SEC ↗ |
| 41 | Northwestern Mutual Wealth… | 500 | 0.0% | $1,875 | 0.0% | Held | 2 | SEC ↗ |
| 42 | Royal Bank Of Canada | 88 | -96.6% | $0 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Balyasny Asset Management L.P. | $12.60M | 0.0% |
| Sei Investments Co | $814,328 | 0.0% |
| Mackenzie Financial Corp | $800,269 | 0.0% |
| Prudential Financial Inc | $50,175 | 0.0% |
Verlaten
| Ameriprise Financial Inc | $958,462 | was 0.0% |
| Group One Trading Llc | $37,423 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 135 houders, 108.23M aandelen, $397.63M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q1 2026 ·
Methodologie ·
Verkrijg dit via de API